{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:34:39Z","timestamp":1782236079364,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Limited data are available regarding the entire spectrum of interstitial lung disease with a progressive fibrosing feature. We investigated the prevalence and prognostic predictive characteristics in patients with PF-ILD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This retrospective cohort study included patients with fibrosing ILD who were investigated between 1 January 2015 and 30 April 2021. We recorded clinical features and outcomes to identify the possible risk factors for fibrosing progression as well as mortality.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of the 579 patients with fibrosing ILD, 227 (39.21%) met the criteria for progression. Clubbing of fingers [odds ratio (OR) 1.52, 95% confidence interval (CI) 1.03 to 2.24, <jats:italic>p<\/jats:italic> = 0.035] and a high-resolution computed tomography (HRCT)-documented usual interstitial pneumonia (UIP)-like fibrotic pattern (OR 1.95, 95% CI 1.33 to 2.86, <jats:italic>p<\/jats:italic> = 0.001) were risk factors for fibrosis progression. The mortality was worse in patients with PF with hypoxemia [hazard ratio (HR) 2.08, 95% CI 1.31 to 3.32, <jats:italic>p<\/jats:italic> = 0.002], in those with baseline diffusion capacity of the lung for carbon monoxide (DLCO) % predicted &amp;lt;50% (HR 2.25, 95% CI 1.45 to 3.50, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), or in those with UIP-like fibrotic pattern (HR 1.68, 95% CI 1.04 to 2.71, <jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Clubbing of fingers and an HRCT-documented UIP-like fibrotic pattern were more likely to be associated with progressive fibrosing with varied prevalence based on the specific diagnosis. Among patients with progressive fibrosing, those with hypoxemia, lower baseline DLCO% predicted, or UIP-like fibrotic pattern showed poor mortality.<\/jats:p>","DOI":"10.3389\/fphar.2022.924754","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:39:49Z","timestamp":1656650389000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuanying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5603\/ARM.a2021.0012","article-title":"Risk Factors for Acute Exacerbation Following Bronchoalveolar Lavage in Patients with Suspected Idiopathic Pulmonary Fibrosis: A Retrospective Cohort Study","volume":"89","author":"Abe","year":"2021","journal-title":"Adv. Respir. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.chest.2017.09.026","article-title":"Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort","volume":"153","author":"Adegunsoye","year":"2018","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e001063","DOI":"10.1136\/bmjresp-2021-001063","article-title":"Use of Peripheral Neutrophil to Lymphocyte Ratio and Peripheral Monocyte Levels to Predict Survival in Fibrotic Hypersensitivity Pneumonitis (fHP): A Multicentre Retrospective Cohort Study","volume":"8","author":"Barratt","year":"2021","journal-title":"BMJ Open Respir. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s2213-2600(20)30554-3","article-title":"Pirfenidone in Patients with Progressive Fibrotic Interstitial Lung Diseases Other Than Idiopathic Pulmonary Fibrosis (RELIEF): a Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"754851","DOI":"10.3389\/fphar.2021.754851","article-title":"Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41379-021-00866-y","article-title":"Hypersensitivity Pneumonitis: New Concepts and Classifications","volume":"35","author":"Churg","year":"2022","journal-title":"Mod. Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000479976","article-title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"B8","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, Diagnosis and Clinical Course of the Spectrum of Progressive-Fibrosing Interstitial Lung Diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing Interstitial Lung Diseases: Knowns and Unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s2213-2600(20)30355-6","article-title":"Progressive Fibrosing Interstitial Lung Disease: Clinical Uncertainties, Consensus Recommendations, and Research Priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00408-020-00370-1","article-title":"Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease","volume":"198","author":"Gibson","year":"2020","journal-title":"Lung"},{"key":"B13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive Interstitial Lung Disease in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the EUSTAR Database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"180078","DOI":"10.1183\/16000617.0078-2018","article-title":"Healthcare Utilisation and Costs in the Diagnosis and Treatment of Progressive-Fibrosing Interstitial Lung Diseases","volume":"27","author":"Holtze","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/bor.0000000000000380","article-title":"Recent Advances in the Pathogenesis, Prediction, and Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease","volume":"29","author":"Johnson","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1378\/chest.105.2.339","article-title":"Clubbing of the Fingers and Smooth-Muscle Proliferation in Fibrotic Changes in the Lung in Patients with Idiopathic Pulmonary Fibrosis","volume":"105","author":"Kanematsu","year":"1994","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12890-019-0996-2","article-title":"Comparison of Disease Progression Subgroups in Idiopathic Pulmonary Fibrosis","volume":"19","author":"K\u00e4rkk\u00e4inen","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180071","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute Exacerbations of Progressive-Fibrosing Interstitial Lung Diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The Natural History of Progressive Fibrosing Interstitial Lung Diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","article-title":"Progressive Fibrosing Interstitial Lung Disease: Prevalence and Clinical Outcome","volume":"22","author":"Kwon","year":"2021","journal-title":"Respir. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11739-021-02883-w","article-title":"Survival of Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension under Therapy with Nintedanib or Pirfenidone","volume":"17","author":"Lacedonia","year":"2022","journal-title":"Intern Emerg. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e000397","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and Survival Data in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib: Pooled Data from Six Clinical Trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"864658","DOI":"10.3389\/fmed.2022.864658","article-title":"Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard","volume":"9","author":"Lee","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2021047","DOI":"10.36141\/svdld.v38i4.11368","article-title":"Phenotypic Clusters and Survival Analyses in Interstitial Pneumonia with Myositis-specific Autoantibodies","volume":"38","author":"Lia","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1084\/jem.20162152","article-title":"Monocyte-derived Alveolar Macrophages Drive Lung Fibrosis and Persist in the Lung over the Life Span","volume":"214","author":"Misharin","year":"2017","journal-title":"J. Exp. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17534666211039771","DOI":"10.1177\/17534666211039771","article-title":"Monitoring and Management of Fibrosing Interstitial Lung Diseases: a Narrative Review for Practicing Clinicians","volume":"15","author":"Nambiar","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","article-title":"Estimates of Epidemiology, Mortality and Disease Burden Associated with Progressive Fibrosing Interstitial Lung Disease in France (The PROGRESS Study)","volume":"22","author":"Nasser","year":"","journal-title":"Respir. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive Fibrosing Interstitial Lung Disease: a Clinical Cohort (The PROGRESS Study)","volume":"57","author":"Nasser","year":"","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung Function Trajectory in Progressive Fibrosing Interstitial Lung Disease","volume":"59","author":"Oldham","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"180077","DOI":"10.1183\/16000617.0077-2018","article-title":"The Epidemiology of Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases at Risk of a Progressive-Fibrosing Phenotype","volume":"27","author":"Olson","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/rheumatology\/keab615","article-title":"The Role of Chest CT in Deciphering Interstitial Lung Involvement: Systemic Sclerosis versus COVID-19","volume":"61","author":"Orlandi","year":"2022","journal-title":"Rheumatol. Oxf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1513\/AnnalsATS.201504-210AW","article-title":"Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation","author":"Richeldi","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/diagnostics11111960","article-title":"High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients","volume":"11","author":"Ruaro","year":"2021","journal-title":"Diagnostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/mcp.0000000000000799","article-title":"Chronic Hypersensitivity Pneumonitis: Real World Diagnostic Criteria","volume":"27","author":"Sharma","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"607689","DOI":"10.3389\/fphar.2020.607689","article-title":"Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis","volume":"11","author":"Skibba","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.rmed.2017.10.021","article-title":"Clubbing in Patients with Fibrotic Interstitial Lung Diseases","volume":"132","author":"van Manen","year":"2017","journal-title":"Respir. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"180073","DOI":"10.1183\/16000617.0073-2018","article-title":"Role of Imaging in Progressive-Fibrosing Interstitial Lung Diseases","volume":"27","author":"Walsh","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.21037\/jtd.2018.03.120","article-title":"Risk Factors for Primary Sj\u00f6gren Syndrome-Associated Interstitial Lung Disease","volume":"10","author":"Wang","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive Fibrosing Interstitial Lung Diseases: Current Practice in Diagnosis and Management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/mcp.0000000000000712","article-title":"Progressive Fibrosing Interstitial Lung Disease: Treatable Traits and Therapeutic Strategies","volume":"26","author":"Wongkarnjana","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","article-title":"The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach","volume":"37","author":"Wuyts","year":"2020","journal-title":"Adv. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10067-021-05964-5","article-title":"Patterns of Lung Diseases Predict Survival in Patients with MPO-ANCA-Associated Vasculitis: a Single-Center Retrospective Study","volume":"41","author":"Yang","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12890-021-01659-4","article-title":"18F-FDG PET\/CT Predicts Acute Exacerbation in Idiopathic Pulmonary Fibrosis after Thoracic Surgery","volume":"21","author":"Yoon","year":"2021","journal-title":"BMC Pulm. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.924754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:39:52Z","timestamp":1656650392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.924754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":49,"alternative-id":["10.3389\/fphar.2022.924754"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.924754","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"924754"}}